Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is currently conducting a clinical study titled A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease. The study aims to evaluate the safety and efficacy of AMG 732, a potential treatment for Thyroid Eye Disease (TED), through subcutaneous doses in both healthy participants and those with TED.
The intervention being tested is AMG 732, administered via subcutaneous injection. The study involves testing various doses of AMG 732 to determine its safety and effectiveness in treating TED.
This interventional study is designed with a randomized allocation and a sequential intervention model. It employs double masking, meaning both participants and investigators are unaware of the treatment assignments, to ensure unbiased results. The primary purpose of the study is treatment-focused.
The study began on May 30, 2024, with the primary completion date yet to be determined. The last update was submitted on July 14, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
The outcome of this study could significantly impact Amgen’s stock performance and investor sentiment, especially if AMG 732 proves effective. Success could position Amgen favorably against competitors in the TED treatment market, potentially leading to increased market share and revenue.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.